Question 1

How does PE-22-28 differ from native spadin?

Accepted Answer

PE-22-28 is a truncated and chemically modified analog of spadin, the propeptide of sortilin that was identified as a natural TREK-1 blocker. The modifications in PE-22-28 improve metabolic stability, increasing its resistance to enzymatic degradation while retaining potent TREK-1 antagonism. This gives PE-22-28 a longer effective half-life and more reliable pharmacokinetics compared to native spadin, which is rapidly degraded in vivo.

Question 2

What is TREK-1 and why is it a target for cognitive enhancement?

Accepted Answer

TREK-1 (TWIK-related potassium channel 1, encoded by the KCNK2 gene) is a two-pore-domain potassium channel widely expressed in the brain, particularly in the hippocampus, prefrontal cortex, and dorsal raphe nucleus. It acts as a background leak channel that dampens neuronal excitability. Genetic deletion of TREK-1 in mice produces animals that are resistant to depression, show elevated serotonin and BDNF levels, and perform better on memory tasks — making pharmacological blockade of this channel an attractive strategy for both mood and cognitive enhancement.

Question 3

Is there any human clinical data for PE-22-28?

Accepted Answer

No. As of the current evidence base, PE-22-28 has been studied exclusively in rodent models and in-vitro preparations. No human clinical trials, case reports, or observational studies have been published. All dosing information circulating in research communities is extrapolated from animal pharmacokinetic data, and human efficacy and safety profiles remain entirely unknown.

Question 4

How does PE-22-28 compare to Selank or Semax for cognitive enhancement?

Accepted Answer

PE-22-28 works through a fundamentally different mechanism — TREK-1 channel blockade leading to BDNF upregulation — whereas Selank modulates GABA and serotonin systems as a tuftsin analog, and Semax acts through melanocortin pathways and BDNF via a different route. The three peptides may have complementary rather than overlapping effects. However, Selank and Semax have substantially more research behind them, including limited human data and decades of clinical use in Russia, while PE-22-28 has only preclinical evidence.

Question 5

What are the known side effects or risks of PE-22-28?

Accepted Answer

In published rodent studies, PE-22-28 has not shown significant adverse effects at doses producing behavioral changes. However, the absence of human safety data means the side-effect profile in humans is entirely unknown. Theoretical concerns include the potential for excessive serotonergic activity (given its mechanism), possible interactions with antidepressant medications that also increase serotonin, and unknown effects on cardiac TREK-1 channels which play a role in cardioprotection during ischemia.

Question 6

Can PE-22-28 be combined with SSRIs or other antidepressants?

Accepted Answer

This combination has not been studied and carries theoretical risk. Because PE-22-28 increases serotonin release through TREK-1 blockade, combining it with SSRIs, SNRIs, or MAOIs could potentially produce excessive serotonergic stimulation. Until interaction data is available, combining PE-22-28 with serotonergic medications should be approached with extreme caution and only under medical supervision.

Question 7

What is the relationship between TREK-1 blockade and BDNF?

Accepted Answer

TREK-1 blockade increases neuronal excitability in hippocampal neurons, leading to enhanced calcium signaling and activation of CREB (cAMP response element-binding protein), which is a transcription factor that drives BDNF gene expression. BDNF in turn promotes synaptic plasticity, long-term potentiation, and neurogenesis in the hippocampus — processes fundamental to learning and memory. This TREK-1 to BDNF cascade provides a mechanistically coherent pathway linking channel blockade to cognitive enhancement.

Question 8

How is PE-22-28 typically administered in research settings?

Accepted Answer

In published animal studies, PE-22-28 has been administered via intravenous and intraperitoneal injection. In the research peptide community, subcutaneous and intranasal routes are discussed, though neither has been validated in published studies. Intranasal delivery is of particular interest for CNS-targeted peptides as it may bypass the blood-brain barrier to some extent, but bioavailability data for PE-22-28 via this route has not been published.

Question 9

Does PE-22-28 cross the blood-brain barrier?

Accepted Answer

The evidence is indirect. PE-22-28 produces clear behavioral effects in rodent models when administered systemically, which strongly suggests central nervous system penetration. However, direct pharmacokinetic studies measuring brain tissue concentrations after systemic administration have not been widely published. The peptide's relatively small size (seven amino acids) and its lipophilic modifications may facilitate BBB transport, but the exact degree of penetration remains to be quantified.

Question 10

Is PE-22-28 banned in competitive sports?

Accepted Answer

PE-22-28 is not specifically named on the WADA Prohibited List. However, WADA's list includes broad categories that can encompass novel peptides, and the general prohibition on substances with pharmacological activity that lack therapeutic approval could apply. Athletes subject to anti-doping testing should consult with their sport's anti-doping authority before using any research peptide, as regulatory interpretations can change and detection methods continue to evolve.

Origin / Manufacturer	Synthetic
Active Components	PE-22-28 heptapeptideBacteriostatic water (for reconstitution)
Storage	Lyophilized: room temperature. Reconstituted: 2–8°C
Shelf Life	Lyophilized 24+ months; reconstituted 30 days refrigerated
Form Factor	Lyophilized powder (5 mg vial)

PE-22-28

Specifications

Frequently Asked Questions

Related Peptides

Dihexa

NA-Selank Amidate

Selank

Semax